Active Ingredient History

  • Now
Efungumab was a drug developed by NeuTec Pharma, intended to treat candidemia in combination with amphotericin B. The European Medicines Agency has twice refused to grant marketing authorization for Mycograb, citing product safety and quality issues.   Wikipedia

More Chemistry
efungumab | hsp90mab | myc-123 | myc-123a | myc-123a myc-123b myc-124 hsp90mab | myc-123b | myc-124 | mycograb


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue